Display options
Cite
Jablonowski H, Sander O, Willers R, et al. The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study. Clin Investig. 1994;72(3):220-4doi: 10.1007/BF00189318.
Jablonowski, H., Sander, O., Willers, R., Adams, O., Bartmann, P., & Wahn, V. (1994). The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study. The Clinical investigator, 72(3), 220-4. https://doi.org/10.1007/BF00189318
Jablonowski, H, et al. "The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study." The Clinical investigator vol. 72,3 (1994): 220-4. doi: https://doi.org/10.1007/BF00189318
Jablonowski H, Sander O, Willers R, Adams O, Bartmann P, Wahn V. The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study. Clin Investig. 1994 Feb;72(3):220-4. doi: 10.1007/BF00189318. PMID: 7912123.
Copy Download .nbib Format: NLM
Share it on

Clin Investig. 1994 Feb;72(3):220-4. doi: 10.1007/BF00189318.

The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study.

The Clinical investigator

H Jablonowski, O Sander, R Willers, O Adams, P Bartmann, V Wahn

Affiliations

  1. Klinik für Gastroenterologie, Heinrich-Heine-Universität Düsseldorf.

PMID: 7912123 DOI: 10.1007/BF00189318

Abstract

To study the efficacy of intravenous immunoglobulin in symptomatic infection with human immunodeficiency virus (HIV) we enrolled 35 patients with CD4 lymphocyte counts below 300/microliter in a randomized three-arm study. In addition to standard HIV treatment (e.g., zidovudine, aerosolized pentamidine), 13 patients were treated with 7.5 g and 11 with 40 g of a 7 S intravenous IgG preparation every 4 weeks over a period of 1 year. A control group of 11 patients remained on standard treatment. Clinical and laboratory parameters, including lymphocyte proliferation and in vitro immunoglobulin synthesis were evaluated prior to intravenous IgG administration. HIV-specific immunological abnormalities such as increased B-cell activation and B-cell immaturity were observed in all three study groups at the beginning of the study. Mitogen-induced lymphocyte proliferation was diminished. These disturbances were not influenced by intravenous IgG treatment. Further laboratory data and the course of the HIV infection (fever, antibiotic treatment, hospitalization, Candida and herpes simplex or cytomegalovirus infection) remained unchanged. Thus, our data with an observation period of 12 months do not support the use of intravenous IgG treatment in adult symptomatic HIV-infected patients with CD4 counts lower than 300/microliter.

References

  1. J Immunol. 1984 Jun;132(6):2857-61 - PubMed
  2. J Clin Invest. 1986 Jan;77(1):294-300 - PubMed
  3. N Engl J Med. 1991 Jul 11;325(2):73-80 - PubMed
  4. JAMA. 1989 Aug 11;262(6):779-83 - PubMed
  5. N Engl J Med. 1991 Jul 11;325(2):110-7 - PubMed
  6. Br Med J (Clin Res Ed). 1987 Aug 1;295(6593):293-6 - PubMed
  7. Infection. 1990 Mar-Apr;18(2):86-90 - PubMed
  8. J Immunol. 1987 Jun 1;138(11):3720-4 - PubMed
  9. J Immunol. 1985 Sep;135(3):1746-51 - PubMed
  10. Clin Exp Immunol. 1989 Jan;75(1):7-11 - PubMed
  11. Lancet. 1992 Nov 28;340(8831):1347 - PubMed
  12. Clin Exp Immunol. 1989 Nov;78(2):153-8 - PubMed
  13. J Infect Dis. 1988 Nov;158(5):983-90 - PubMed
  14. Am J Med. 1985 May;78(5):728-36 - PubMed
  15. Clin Immunol Immunopathol. 1986 Jun;39(3):359-67 - PubMed
  16. J Pediatr. 1985 Sep;107(3):352-7 - PubMed
  17. J Infect Dis. 1991 Feb;163(2):240-6 - PubMed

Substances

MeSH terms

Publication Types